Results 201 to 210 of about 58,391 (264)

Redefining functional high‐risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation

open access: yesCancer, Volume 132, Issue 14, 15 July 2026.
Abstract Background Functional high‐risk (FHR) multiple myeloma (MM) was historically defined as progression within 18 months of starting therapy, with expected subsequent overall survival (OS) <2 years. The optimal definition of FHR in the era of combined quadruplet therapy (QUAD) + autologous stem cell transplantation (ASCT) is unknown.
Gayathri Ravi   +9 more
wiley   +1 more source

CD38 expression by neonatal human naive CD4+ T cells shapes their distinct metabolic and tolerogenic properties. [PDF]

open access: yesJ Clin Invest
Dwyer LR   +14 more
europepmc   +1 more source

Immunological characteristics of children with autism spectrum disorder and comorbid atopic dermatitis. [PDF]

open access: yesFront Pediatr
Shi H   +12 more
europepmc   +1 more source

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance

open access: yesInternational Journal of Cancer, Volume 159, Issue 2, Page 410-422, 15 July 2026.
What's new? Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor to multiple myeloma, sharing substantial genetic features with overt malignancy. Given evidence implicating autophagy in myeloma risk, this study examined whether genetic variations in autophagy‐related genes influence MGUS susceptibility.
José Manuel Sánchez‐Maldonado   +54 more
wiley   +1 more source

Efficacy and Safety of Anti-CD38 Antibody-Containing Triplet Regimens in Frail Patients with Multiple Myeloma. [PDF]

open access: yesCancers (Basel)
Iriuchishima H   +6 more
europepmc   +1 more source

Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy. [PDF]

open access: yesKidney Int Rep
Cheddadi Y   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy